1.	Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CFEM345C2403, NCT00171847
2.	An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin During Pregnancy or Within 6 Months Prior to Conception Phase: Phase IV Type: Natural history/Epidemiology Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: H4621g, NCT00833963
3.	Effects of Granulocyte Colony-Stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: D-0140, NCT00169104
4.	Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients Phase: Phase III, Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: GEICAM/2006-14, Nº EudraCT 2007-007031-13, NCT00841828
5.	Phase III Randomized Study of First-Line Trastuzumab (Herceptin) Alone Followed By Combination Trastuzumab and Paclitaxel Versus First-Line Combination Trastuzumab and Paclitaxel in Women With HER2-Overexpressing Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: SWS-SAKK-22/99, EU-99028, NCT00004935
6.	Phase III Randomized Study of Four Schedules of Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Patients With Node-Positive or High-Risk Node-Negative Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0221, S0221, NCT00070564
7.	Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: ID99-146, NCT00038402
8.	Phase III Randomized Study of Neoadjuvant Epirubicin Hydrochloride, Cyclophosphamide, and Docetaxel With Versus Without Capecitabine and/or Trastuzumab (Herceptin®) Followed by Surgery in Women With Stage I-III Primary Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GBG-GEPARQUATTRO, GBG-40, EU-205101, AVENTIS-GBG-GEPARQUATTRO, ROCHE-AVENTIS-GBG-GEPARQUATTRO, EUDRACT-2005-001546-17, NCT00288002
9.	ErbB2 Over-Expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF104383, NCT00272987
10.	A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Subjects With Metastatic Breast Cancer Receiving Standard Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR005143, NCT00338286
11.	Phase III Randomized Study of Adjuvant Trastuzumab (Herceptin®) Administered for 6 Months Versus 12 Months in Women With Nonmetastatic, Resectable Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: INCA-PHARE, PHARE, INCA-RECF0146, EUDRACT-2006-000070-67, NCT00381901
12.	A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO20231, NCT00391092
13.	Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 74 Sponsor: Other Protocol IDs: HERNATA, NCT00430001
14.	A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML19944, NCT00444587
15.	Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-Associated Cardiotoxicity Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: M06HER, NCT00459771
16.	A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NSABP B-41, NCT00486668
17.	ALTTO(Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation)Study; BIG 2-06/N063D Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: EGF106708, BIG 2-06/N063D/MAC13, NCT00490139
18.	Phase III Randomized Study of Neoadjuvant Combination Chemotherapy Comprising Fluoroucacil, Epirubicin Hydrochloride, and Cyclophosphamide Followed by Paclitaxel and Trastuzumab (Herceptin®) Versus Neoadjuvant Paclitaxel and Trastuzumab Followed by Combination Chemotherapy Comprising Fluoroucacil, Epirubicin Hydrochloride, Cyclophosphamide and Trastuzumab in Women With Palpable and Operable Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ACOSOG-Z1041, Z1041, NCT00513292
19.	Phase III Randomized Study of First-Line Chemotherapy and Trastuzumab (Herceptin®) With or Without Bevacizumab in Patients With HER-2/NEU Overexpressing Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1105, E1105, NCT00520975
20.	Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF106903, BIG 1-06, NCT00553358
21.	A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer (CLEOPATRA) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TOC4129g, WO20698, NCT00567190
22.	A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer Phase: Phase III Type: Genetics, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GBG 44, EudraCT No.: 2006-005834-19, NCT00567554
23.	Phase III Randomized Study of Two Different Regimens of Adjuvant Chemotherapy and Trastuzumab (Herceptin®) in Women With HER2-Positive Stage I-IIIA Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: AOUMODENA-SHORT-HER, EudraCT 2007-004326-25, EUDRACT-2007-004326-25, EU-20825, NCT00629278
24.	The Synergism Or Long Duration (SOLD) Study Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Protocol number FBCSG-01-2007, EudraCT number 2007-002016-26, NCT00593697
25.	Six vs 12 Months of Transtuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CT/04.23, NCT00615602